Azenta, Inc. (AZTA) 2025 Fiscal Year 10-K Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Azenta, Inc. for the fiscal year ended September 30, 2025. Azenta is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The company operates through two primary segments: Sample Management Solutions (automated storage, cryogenics, and repository services) and Multiomics (genomic services). The company divested its semiconductor business in 2022 and is currently pursuing the sale of its B Medical Systems business, which is classified as a discontinued operation.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $593.8 million | $573.4 million | +3.6% |
| Gross Profit | $270.3 million | $254.6 million | +6.2% |
| Gross Margin | 45.5% | 44.4% | +110 bps |
| Operating Loss | $(26.8) million | $(51.3) million | Improvement |
| Income from Continuing Ops | $24.5 million | $(24.4) million | Turnaround |
| Net Loss | $(55.8) million | $(164.9) million | Improvement |
| Cash & Equivalents | $279.8 million | $280.0 million | Flat |
| Marketable Securities | $262.7 million | $200.6 million | Increased |
| Goodwill | $702.4 million | $691.4 million | Increased |
Note: Net Loss includes a $80.2 million loss from discontinued operations (B Medical Systems). Income from continuing operations was positive due to a significant tax benefit.
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability from continuing operations ($24.5 million income) compared to a loss of $24.4 million in 2024. This was primarily driven by a $45.6 million tax benefit from a worthless stock deduction on a foreign subsidiary investment, partially offset by lower interest income.
- Revenue Growth: Total revenue grew 3.6% year-over-year. Sample Management Solutions revenue increased 1.8%, while Multiomics revenue grew 5.8%.
- Discontinued Operations: The B Medical Systems business was classified as held for sale. This resulted in a $93.1 million estimated loss on assets held for sale in 2025, significantly impacting the consolidated net loss.
- Cost Management: Operating expenses decreased to $297.1 million from $305.9 million in 2024, driven by lower R&D, SG&A, and restructuring charges, despite higher transformation costs.
Guidance, Outlook, and Risks
Management Commentary: Management continues to focus on cost reduction and productivity improvement through transformation initiatives. The company is simplifying its portfolio by selling B Medical Systems to focus on core life sciences segments. No specific forward-looking financial guidance was provided in the text, but management expects to complete the B Medical Systems sale by the end of December 2025.
Material Weaknesses in Internal Controls: The company identified three material weaknesses in internal control over financial reporting as of September 30, 2025:
- Controls related to the review of the cash flow statement.
- Controls related to the preparation and review of account reconciliations.
- Controls over the classification of certain costs (Cost of Revenue vs. Operating Expenses).
Key Risks:
- Geopolitical & Trade: Exposure to US-China tensions, tariffs, and the BIOSECURE Act which could impact supply chains and operations in China.
- Cybersecurity: Risks related to data privacy (GDPR, CCPA) and potential breaches affecting genomic data.
- Goodwill Impairment: Significant goodwill balance ($702.4 million) remains at risk if future performance or stock price declines.
- Internal Controls: Failure to remediate material weaknesses could lead to restatements or loss of investor confidence.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the likelihood of the $45.6 million worthless stock deduction being sustained upon IRS review, as this was the primary driver of the 2025 income from continuing operations.
- Discontinued Operations Sale: Monitor the progress of the B Medical Systems sale and the final valuation to confirm the $93.1 million impairment estimate.
- Internal Control Remediation: Review future filings (10-Q) for progress on remediating the three identified material weaknesses in financial reporting controls.
- China Exposure: Assess the impact of the "Bulk Transfer Rule" and potential tariffs on the Multiomics segment, which has significant operations in China.
- Segment Margins: Analyze the divergence between the profitable Sample Management Solutions segment and the loss-making Multiomics segment to understand long-term profitability drivers.